{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "ACE-2",
      "COVID-19",
      "RAS",
      "SARS-CoV-2"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34151392",
  "DateCompleted": {
    "Year": "2021",
    "Month": "07",
    "Day": "08"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "09",
    "Day": "28"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "06",
        "Day": "21"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1007/s00210-021-02108-z"
    ],
    "Journal": {
      "ISSN": "1432-1912",
      "JournalIssue": {
        "Volume": "394",
        "Issue": "7",
        "PubDate": {
          "Year": "2021",
          "Month": "Jul"
        }
      },
      "Title": "Naunyn-Schmiedeberg's archives of pharmacology",
      "ISOAbbreviation": "Naunyn Schmiedebergs Arch Pharmacol"
    },
    "ArticleTitle": "The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.",
    "Pagination": {
      "StartPage": "1589",
      "EndPage": "1593",
      "MedlinePgn": "1589-1593"
    },
    "Abstract": {
      "AbstractText": [
        "In March 2019, the global COVID-19 pandemic caused by the novel SARS-CoV-2 coronavirus began. The first cases of SARS-CoV-2 infection occurred in November 19 in Wuhan, China. Preventive measures taken have not prevented the rapid spread of the virus to countries around the world. To date, there are approximately 3 million deaths, and a massive worldwide vaccination campaign has recently begun. SARS-CoV-2 uses the ACE-2 protein as an intracellular carrier. ACE-2 is a key component of the renin-angiotensin system (RAS), a key regulator of cardiovascular function. Considering the key role of ACE-2 in COVID-19 infection, both as an entry receptor and as a protective role, especially for the respiratory tract, and considering the variations of ACE-2 during the phases of viral infection, it is clear the important role that pharmacological regulation of RAS and ACE-2 may take. In this article, we describe the importance of ACE-2 in COVID-19 infection, the pharmacological aspects of a modulation with RAS-modifying agents, new therapeutic strategies, trying to provide a deep understanding and explanation of the complex mechanisms underlying the relationship between the virus and ACE-2, providing opinions and personal hypotheses on the best strategies of therapeutic intervention."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-9298-6783"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pharmaceutical Department, Usl Umbria 1, A. Migliorati Street, 06132, Perugia, Italy. francesco.ferrara@uslumbria1.it."
          }
        ],
        "LastName": "Ferrara",
        "ForeName": "Francesco",
        "Initials": "F"
      },
      {
        "Identifier": [
          "0000-0003-2623-166X"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pharmaceutical Department, Usl Umbria 1, A. Migliorati Street, 06132, Perugia, Italy."
          }
        ],
        "LastName": "Vitiello",
        "ForeName": "Antonio",
        "Initials": "A"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Germany",
    "MedlineTA": "Naunyn Schmiedebergs Arch Pharmacol",
    "NlmUniqueID": "0326264",
    "ISSNLinking": "0028-1298"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Recombinant Proteins"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "ACE2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "Naunyn Schmiedebergs Arch Pharmacol. 2022 Jan;395(1):117-118",
      "PMID": "34738150"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "metabolism",
        "therapeutic use"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "enzymology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Host-Pathogen Interactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Recombinant Proteins"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Renin-Angiotensin System"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Internalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "The authors declare no completing interests."
}